The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aakanksha M Chawda
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 7.3 pts more than Nifty Microcap 250 and 7.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aakanksha M Chawda, a member of the promoter group of Oxygenta Pharmaceutical Ltd, has disclosed the sale of 10,12,800 equity shares (2.74% of total equity capital) on April 22, 2025. The transaction was carried out via inter-se transfer pursuant to a Memorandum of Understanding dated September 30, 2024. Following this sale, the individual promoter's holding reduced from 15,82,500 shares (4.28%) to 5,69,700 shares (1.54%). The total equity capital of the company remains at 3,69,83,500 shares of Rs. 10 each. No shares are currently pledged or encumbered.
Since this is an inter-se transfer within the promoter group (not an open-market sale), it likely reflects an internal restructuring of promoter holdings rather than an exit by the promoter family. Retail investors generally need not be alarmed, but should watch for the corresponding acquisition disclosure to understand the full picture of how promoter shareholding is being reshuffled.